EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Biofil Chemicals & Pharmaceuticals EBITDA Margin % Related Terms
Biofil Chemicals & Pharmaceuticals EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524396 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biofil Chemicals & Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofil Chemicals & Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofil Chemicals & Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Biofil Chemicals & Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofil Chemicals & Pharmaceuticals (BOM:524396) has a EBITDA Margin % of 7.18% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Biofil Chemicals & Pharmaceuticals and its competitors. This is near median its historical median of 6.68. Over the past decade, Biofil Chemicals & Pharmaceuticals' EBITDA Margin % has ranged from 3.26 to 20.50. According to the industry distribution chart, Biofil Chemicals & Pharmaceuticals ranks #459 out of 952 companies in the Drug Manufacturers industry, placing it in the top 48.2%.
Is Biofil Chemicals & Pharmaceuticals' EBITDA Margin % too high?
Biofil Chemicals & Pharmaceuticals' current EBITDA Margin % of 7.18% is near median its 10-year median of 6.68. Over the past 10 years, this metric has ranged from a low of 3.26 to a high of 20.50. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Biofil Chemicals & Pharmaceuticals' value of 7.18% is 42.4% below this industry median. Based on the distribution chart, Biofil Chemicals & Pharmaceuticals ranks #459 out of 952 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Biofil Chemicals & Pharmaceuticals has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biofil Chemicals & Pharmaceuticals' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biofil Chemicals & Pharmaceuticals ranks #459 out of 952 companies for EBITDA Margin %. This puts Biofil Chemicals & Pharmaceuticals in the upper half of its industry. The industry median EBITDA Margin % is 12.47. Biofil Chemicals & Pharmaceuticals' value of 7.18% is 42.4% below this benchmark. Historically, Biofil Chemicals & Pharmaceuticals' own EBITDA Margin % has ranged from 3.26 to 20.50 over the past decade. While the company's 10-year median is 6.68 vs. the industry median of 12.47, Biofil Chemicals & Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biofil Chemicals & Pharmaceuticals's current EBITDA Margin % of 7.18% is 42.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Biofil Chemicals & Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofil Chemicals & Pharmaceuticals's current EBITDA Margin % is 7.18%, which is near median its own 10-year median of 6.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofil Chemicals & Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Biofil Chemicals & Pharmaceuticals (BOM:524396) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹41.83, compared to a current price of ₹35.11 — trading 16.1% below its estimated fair value. The current EBITDA Margin % is 7.18%, which is near median its 10-year median of 6.68 and 42.4% below the Drug Manufacturers industry median of 12.47. Biofil Chemicals & Pharmaceuticals' overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Biofil Chemicals & Pharmaceuticals (BOM:524396), the current EBITDA Margin % is 7.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofil Chemicals & Pharmaceuticals (BOM:524396) Overvalued in 2026?
Based on GuruFocus' analysis, Biofil Chemicals & Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹35.11 is trading 16.1% below its estimated GF Value™ of ₹41.83.
GuruFocus considers Biofil Chemicals & Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for BOM:524396:
EBITDA Margin %: 7.18% (near median its 10-year median of 6.68)
GF Value™: ₹41.83 vs. price of ₹35.11 (16.1% below fair value)
Industry Position: 42.4% below the Drug Manufacturers median (#459 of 952)
No single metric tells the full story. See the BOM:524396 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofil Chemicals & Pharmaceuticals Business Description
Biofil Chemicals & Pharmaceuticals Ltd is an Indian pharmaceutical company. It deals in the manufacturing and trading of pharmaceuticals. Further, the company also deals in providing job work facilities with respect to the manufacturing of pharmaceutical drugs. Its product portfolio comprises basic drugs and pharmaceuticals such as sodium citrate, sodium chloride, ferrous sulphate, micro crystalline cellulose, dicyclomine hydrochloride, and others. The company's operating segments are: Pharma, which derives maximum revenue, and Chemicals. Geographically, it caters to both domestic and international markets.
69GF Score
Get the complete analysis for BOM:524396
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524396 has been successfully added to your 
